Moody’s upgrades Agnico Eagle’s rating to A3 on debt reduction
SOUTH SAN FRANCISCO, Calif. - Alumis Inc. (NASDAQ: ALMS), a biopharmaceutical company specializing in immune-mediated diseases trading near its 52-week low of $4.46, announced it will present new data on A-005, a CNS-penetrant TYK2 inhibitor, at the ACTRIMS Forum 2025 on Friday. With a market capitalization of $249 million, InvestingPro analysis indicates the company maintains a strong liquidity position with more cash than debt on its balance sheet. The presentations will reveal findings on A-005’s potent inhibition of TYK2 signaling in immune and CNS resident cells, which could play a role in treating neuroinflammatory diseases.
Jörn Drappa, M.D., Chief Medical (TASE:BLWV) Officer at Alumis, stated that A-005 is the first allosteric TYK2 inhibitor reported to cross the blood-brain barrier, potentially offering a novel treatment for diseases associated with CNS inflammation. According to Drappa, Phase 1 clinical trial data showed A-005 to be well tolerated with maximal TYK2 inhibition across various doses, supporting the progression to a Phase 2 trial for multiple sclerosis patients in the latter half of 2025.
The Phase 1 trial assessed the safety, tolerability, and pharmacokinetics of A-005 in 135 healthy volunteers through single and multiple ascending doses. The study aimed to establish a PK/PD relationship using pharmacodynamic markers, including pSTAT levels. According to InvestingPro data, Alumis maintains a healthy current ratio of 11.26, though analysts note the company is rapidly burning through its cash reserves. InvestingPro subscribers have access to 12 additional key insights about ALMS’s financial health and market position.
A-005 is being developed as a first-in-class treatment option for neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. It is designed to inhibit TYK2 maximally and penetrate the blood-brain barrier, thereby potentially treating within both the CNS and periphery. TYK2 is a key protein in proinflammatory cytokine signaling, and A-005’s Phase 1 trial completion sets the stage for its Phase 2 trial in multiple sclerosis.
Alumis focuses on developing oral therapies with a precision approach to enhance clinical outcomes for patients with immune-mediated diseases. Their pipeline, supported by a proprietary precision data analytics platform, includes ESK-001 and other preclinical programs targeting a range of immune-mediated diseases. The company, incubated by Foresite Labs, is led by industry veterans and aims to pioneer precision drug development. While the stock has experienced a significant 66% decline over the past year, analyst consensus remains bullish with price targets ranging from $17 to $29. Get comprehensive financial analysis and real-time alerts with InvestingPro.
The information in this article is based on a press release statement from Alumis Inc.
In other recent news, Alumis Inc. has announced a significant development with its new Severance and Change in Control Plan, which provides severance benefits for employees terminated without cause during specified periods. The plan includes severance payments, bonuses, and health insurance coverage, with additional benefits for executive officers. Meanwhile, Alumis and ACELYRIN, Inc. have entered into a definitive all-stock merger agreement, with Alumis shareholders set to own 55% of the combined entity. The merger aims to create a strong biopharmaceutical entity focusing on immune-mediated diseases, with a projected cash position of $737 million to fund operations into 2027.
In related analyst activity, H.C. Wainwright adjusted its price target for Alumis to $19, down from $26, while maintaining a Buy rating, citing the merger as a strategic move for capital acquisition. Additionally, Oppenheimer initiated coverage on Alumis with an Outperform rating and a $32 price target, highlighting the potential of its lead product candidate, ESK-001, in treating psoriasis and systemic lupus erythematosus. In a separate development, ACELYRIN received an unsolicited buyout proposal from Concentra Biosciences, offering $3.00 per share plus a contingent value right. ACELYRIN’s board remains committed to its merger with Alumis while advising shareholders that no immediate action is necessary regarding the buyout interest.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.